139 In the index

Setmelanotide SETM

An FDA-approved medication (Imcivree) for obesity caused by specific rare genetic conditions. Human studies show substantial, lasting weight loss in these specific genetic cases, though it isn't approved or effective for general weight loss outside of them.

Also known as Imcivree, Setmelanotida, N7T15V1FUY, Setmelanotidum, RefChem:58308, Setmelanotide (RM-493), Setmelanotide [USAN:INN], Setmelanotide [USAN]

Effects Lose fat

Routes Subcutaneous

Legal status Prescription drug

WADA Not listed

Molecular Structure of C₄₉H₆₈N₁₈O₉S₂

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C49H68N18O9S2
Molar mass: 1117.3
CAS: 920014-72-8
PubChem CID: 11993702
IUPAC name: (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide
InChIKey: HDHDTKMUACZDAA-PHNIDTBTSA-N

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 3 mg/day (adults) or weight-based dosing (pediatric)

Reported range 1-3 mg/day, titrated

Route Subcutaneous injection

Frequency Once daily

Duration Chronic/ongoing (as prescribed)

FDA-approved melanocortin-4 receptor agonist (Imcivree) for obesity due to specific rare genetic conditions, not for general weight loss.

Where this comes from FDA prescribing information

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.